Home › Merck to Present New Data for Investigational Hepatitis C Treatments MK-5172 and MK-8742 at EASL Annual Meeting/The International Liver Congress 2014
 

Keywords :   


Merck to Present New Data for Investigational Hepatitis C Treatments MK-5172 and MK-8742 at EASL Annual Meeting/The International Liver Congress 2014

2014-03-24 12:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. Company to Initiate Phase 3 Clinical Development Program in Q2 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new Phase 2 data for its two investigational hepatitis C virus (HCV) treatments - MK-5172, an investigational HCV NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor are scheduled to be presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), also known as The International Liver Congress 2014. Language: English Contact: MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 908-423-6154orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data international present annual

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Indian spices face heat over global safety concerns
15.05'Corrupt ship inspectors demand our food and cargo'
15.05Taylor Swift Eras Tour to boost UK spending by 1bn, says report
15.05Three ways to win the rental property race
15.05Renters in scrum for homes as listing time slashed
14.05Nu Skin Releases 2023 Social Impact and Sustainability Report
14.05P&G Unveils Plans to Feature Brands During the Olympic and Paralympic Games Paris 2024
14.05The LOccitane Group Appoints Evelyne LY-Wainer Managing Director Global Travel Retail
More »